Of note in both FLT3-mutated and FLT3-wild type AML, midostaurin has demonstrated immune-modulatory effects as shown by a reduction in the CD4+ CD25+ cells proportion, mRNA levels of FOXP3 and IL-10 and TNFα levels (147). Here, CD4 is linked to acute myeloid leukemia.